title: Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS.
abstract: BACKGROUND
  Elevation of serum proinflammatory advanced glycation end products (AGEs) is involved in the pathogenesis of polycystic ovary syndrome (PCOS). The soluble receptor for AGEs (sRAGE) acts as a decoy by binding circulating AGEs. Vitamin D supplementation attenuates the deposition of AGEs in the vascular system of diabetic animals and improves some metabolic aspects of vitamin D-deficient women with PCOS. Additionally, serum anti-Mullerian hormone (AMH) is elevated in women with PCOS, reflecting abnormal ovarian folliculogenesis.
  
  
  OBJECTIVE
  The objective of the study was to evaluate the effect of 1,25 dihydroxyvitamin D3 (vit D3) supplementation on serum sRAGE and AMH in vitamin D-deficient women with PCOS. DESIGN, SETTINGS, PARTICIPANTS, AND INTERVENTION: Sixty-seven women with (n = 22) or without (control; n = 45) PCOS who were diagnosed with vitamin D deficiency were enrolled. Fifty-one women were replaced with oral vit D3 for 8 weeks (16 with PCOS and 35 controls) and 16 women were not treated (six with PCOS and 10 controls). Serum 25-hydroxyvitamin D (25 OH-D), sRAGE, and AMH concentrations were measured at baseline and after vit D3 supplementation in the treated group and 8 weeks apart in the nontreated group.
  
  
  METHODS
  Changes in serum sRAGE and AMH concentrations after vit D3 replacement were measured.
  
  
  RESULTS
  In all participants, there was a negative correlation between body mass index and serum sRAGE levels (r = -0.3, P = .01). In women with PCOS, but not in controls, vit D3 increased serum sRAGE (P = .03) and decreased serum AMH levels (P < .001). The increase in serum sRAGE positively correlated with the increase in serum 25 OH-D after supplementation in women with PCOS (r = 0.6, P = .01).
  
  
  CONCLUSIONS
  In women with PCOS, vit D3 might exert a protective effect against the inflammatory action of AGEs by increasing circulating sRAGE. The normalization in serum AMH induced by vit D3 replacement suggests an improvement in folliculogenesis.
authors.affiliation: Department of Obstetrics and Gynecology (M.I., H.M., D.B.S.), Maimonides Medical Center, Brooklyn, New York 11219; and Department of Obstetrics, Gynecology and Reproductive Sciences (Z.M.), Division of Reproductive Endocrinology and Infertility, University of Vermont College of Medicine, Burlington, Vermont 05401.
authors.forename: Mohamad
authors.initials: M
authors.lastname: Irani
authors.forename: Howard
authors.initials: H
authors.lastname: Minkoff
authors.forename: David B
authors.initials: DB
authors.lastname: Seifer
authors.forename: Zaher
authors.initials: Z
authors.lastname: Merhi
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000097:blood*; D016896:Treatment Outcome; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy*
chemical_list: D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; C118756:dihydroxy-vitamin D3; D014807:Vitamin D; D054304:Anti-Mullerian Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone